Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 16/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18810016 | 0.74 | JAK2 (0.35) | HCAR2 | |
| SCHEMBL18021165 | 0.73 | JAK2 (0.34) | FGFR4HCAR2 | |
| SCHEMBL18021173 | 0.73 | JAK2 (0.34) | FGFR4HCAR2 | |
| SCHEMBL18021184 | 0.73 | JAK2 (0.34) | FGFR4HCAR2 | |
| SCHEMBL24587149 | 0.72 | DGAT2 (0.47) | — | |
| SCHEMBL29887475 | 0.71 | FAAH (0.42) | — | |
| SCHEMBL24588367 | 0.71 | FAAH (0.42) | — | |
| SCHEMBL29083198 | 0.71 | FGFR4 (0.37) | FGFR4 | |
| SCHEMBL29083202 | 0.71 | FGFR4 (0.37) | FGFR4 | |
| SCHEMBL18810384 | 0.71 | RORC (0.51) | FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240140938-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-05-02 | — | — | US | disclosed |
| CN-116783187-A | Preparation of tetrahydroindazole derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors | 默沙东有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022140169-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540132-B2 | Preparation of tetrahydroindazole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | HTR7 2519/4885FGFR4 1334/4885HCAR2 1059/4885 |
| US-20240140938-A1 | PREPARATION OF TETRAHYDROINDAZOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | HTR7 3121/4885FGFR4 1157/4885HCAR2 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.